B7-H3 Antibodies

Santa Cruz Biotechnology features a diverse variety of B7-H3 monoclonal antibodies for research focused on immune regulation and tumor biology. B7-H3 monoclonal antibodies are validated for multiple applications, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). B7-H3, also known as CD276, is a member of the B7 family of immune checkpoint proteins and plays a critical role in modulating T-cell responses. B7-H3 expression is frequently upregulated in various cancers, making it a significant target for therapeutic intervention and a potential biomarker for tumor progression. Understanding B7-H3 function is essential for developing strategies to enhance anti-tumor immunity. Researchers can investigate B7-H3 expression patterns across different tissue types and cellular conditions. Advanced imaging techniques combined with B7-H3 monoclonal antibodies enable detailed visualization of protein localization and interactions. Comprehensive studies of B7-H3 cellular distribution and regulation contribute to deeper understanding of immune system mechanisms. Santa Cruz Biotechnology monoclonal antibodies support researchers worldwide in advancing scientific knowledge of immune checkpoint regulation and cancer biology.